Key facts
- Notable investors include iAccel (Seongnam-si).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ethicstem
- ·The full record, as it builds
Funding rounds
No funding rounds for Ethicstem are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ethicstem
Developer of cell-based therapeutic intended to address degenerative ocular conditions. The company's platform focuses on differentiating pluripotent cells into functional corneal tissue, incorporates protocols for producing cells that can potentially replace non-regenerative cell populations, and supports development toward clinical application, enabling healthcare providers and researchers to explore alternatives to traditional surgical interventions for patients with persistent corneal disease by offering a scalable biologic approach that may improve treatment accessibility and outcomes in ophthalmology.
- Sector
- Healthcare
- HQ
- Hanam, South Korea
- Founded
- 2023
- Website
- ethicstem.kr/
- Ownership
- Privately Held (backing)
Ethicstem doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ethicstem shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ethicstem in its N-PORT filings yet. We sweep new filings monthly.